The rise of med-spas, weight-loss clinics, and concierge medical practices has been significant in recent years, as patients increasingly opt for membership models that allow for direct payment and same-day access to healthcare providers. Despite this shift to cash-pay models, many of these clinics still depend on outdated software designed for traditional insurance-based care.
Enter VITL, a Nashville-based startup that launched 18 months ago with the aim of addressing a critical technology gap in the cash-pay medical sector. VITL has developed an e-prescribing platform tailored specifically for these businesses, allowing for more efficient management and processing of prescriptions. Recently, the company secured $7.5 million in Series A funding led by SignalFire.
The founder and CEO, Charlie Jordan, recognised the burdensome nature of prescription management for treatments not covered by insurance. Many healthcare providers resort to faxes or phone calls to transmit prescriptions to compounding pharmacies, leading to inefficiencies and uncertainties regarding costs and timelines. VITL’s platform streamlines this process by linking clinics to a nationwide network of compounding pharmacies, enabling real-time price comparisons and tracking akin to services like Amazon.
Jordan emphasizes the dramatic reduction in prescription processing time, claiming it can be shortened from several minutes to mere seconds. This efficiency is particularly significant for clinics that handle numerous orders daily, translating into substantial time savings—up to two full workdays per month, according to VITL.
The startup’s impact has been notable, reporting the onboarding of over 630 clinics and achieving at least $10 million in annual recurring revenue (ARR) within just over a year of operations. However, this figure still represents a small portion of a broader market that includes tens of thousands of clinics in the United States. With rising consumer interest in GLP-1 drugs like Ozempic and Wegovy, alongside aesthetic treatments such as Botox, the number of cash-pay healthcare providers is projected to grow further.
Interestingly, VITL did not actively seek investment from SignalFire; rather, the venture capital firm recognized the startup’s rapid growth as a testament to its potential. SignalFire, known for utilising data and AI to identify promising companies, became instrumental in securing the recent funding round.
VITL faces competition from established e-prescribing entities like Surescripts and other platforms that integrate prescription functionalities into broader electronic health record systems. What distinguishes VITL, however, is its unwavering focus on meeting the operational needs of the cash-pay medical landscape, setting it apart from its competitors.
As the demand for efficient technological solutions in the evolving healthcare space intensifies, VITL is positioning itself as a leader in a burgeoning sector, poised for continued growth and innovation.
Fanpage:Â TechArena.au
Watch more about AI – Artificial Intelligence
